Business
Ozempic vs Wegovy
(Steve Christo-Corbis/Getty Images)

Meds made by Novo Nordisk, Pfizer, Eli Lilly among those up for Medicare price negotiations

The 15 drugs include GLP-1s like Ozempic and Wegovy and were used by over 5 million Americans.

J. Edward Moreno

Ozempic is among the new slate of medications that will be subject to price negotiations for Medicare, the Department of Health and Human Services said Friday.

The Inflation Reduction Act of 2022 gave HHS the power to negotiate prices with drug manufacturers for medications covered under Medicare, a government health-insurance program for seniors. Medicare has negotiated prices for 10 drugs so far.

PhRMA, an industry trade organization, has long opposed Medicare price negotiations. In a Friday statement, the group called the price negotiations “dangerous” and said it stifles innovations. Major drugmakers have also sued the government to end the program.

The 15 drugs selected for price negotiations announced on Friday were used by 5.3 million people covered by Medicare between November 2023 and October 2024 and cost the government $41 billion, HHS said. Those medications are:

  • Ozempic; Rybelsus; Wegovy: various brand names for semaglutide, a popular weight-loss medication made by Novo Nordisk. 

  • Trelegy Ellipta: an inhaler made by GlaxoSmithKline. 

  • Xtandi: a medication that treats prostate cancer produced by Pfizer. 

  • Pomalyst: made by Bristol Myers Squibb and used to treat a blood cancer and a cancer that develops in people with HIV.

  • Ibrance: a breast-cancer treatment made by Pfizer. 

  • Ofev: a medication used to treat lung cancer made by Boehringer Ingelheim.

  • Linzess: treats IBS and constipation, made by Ironwood and AbbVie.

  • Calquence: treats certain types of blood cancers, made by AstraZeneca.

  • Austedo; Austedo XR: treats tardive dyskinesia or Huntington’s disease, made by Teva Pharmaceuticals. 

  • Breo Ellipta: an inhaler used for the maintenance treatment of asthma and chronic obstructive pulmonary disease, made by GSK. 

  • Tradjenta: used to treat Type 2 diabetes, made by Boehringer Ingelheim and Eli Lilly. 

  • Xifaxan: used to treat traveler’s diarrhea and IBS, made by Bausch Health. 

  • Vraylar: used to trade schizophrenia and bipolar disorder, made by AbbVie.

  • Janumet; Janumet XR: used to treat Type 2 diabetes, made by Merck & Co.

  • Otezla: used to treat certain types of psoriasis and psoriatic arthritis, made by Amgen. 

More Business

See all Business
Foam party!

Crocs’ prince charming

ByChrisStokel-Walker

FriMar 272026

business
Max Knoblauch

Netflix is hiking its prices again

Netflix is raising its subscription prices for the fourth time in four years, a move first spotted by Android Authority.

Per Netflix’s US pricing page, the cost of an ad-supported plan is climbing $1 to $8.99 per month, while the cost of a standard ad-free plan is going up $2 to $19.99 per month. The premium tier has also risen $2 to $26.99 per month.

The streamer last raised its subscription costs more than a year ago in January 2025. It also hiked prices in 2023, 2022, 2020, and 2019. Netflix shares climbed about 2% on the news.

“Our approach remains the same: we continue offering a range of prices and plans to meet a variety of needs, and as we deliver more value to our members we are updating our prices to enable us to reinvest in quality entertainment and improve their experience by updating our prices,” said a Netflix spokesperson, in a statement to Sherwood News.

Netflix is hiking your prices yet again: Standard, premium, and ad-supported all going up

Netflix is hiking your prices yet again: Standard, premium, and ad-supported all going up

The streamer last raised its subscription costs more than a year ago in January 2025. It also hiked prices in 2023, 2022, 2020, and 2019. Netflix shares climbed about 2% on the news.

“Our approach remains the same: we continue offering a range of prices and plans to meet a variety of needs, and as we deliver more value to our members we are updating our prices to enable us to reinvest in quality entertainment and improve their experience by updating our prices,” said a Netflix spokesperson, in a statement to Sherwood News.

Hyunsoo Rim
going clear
3/26/26
How record wait times at US airports are sending one app soaring

Demand for Clear Secure services are surging as travelers look to bypass TSA lines.

Group of people standing in queue at boarding gate
Claire Yubin Oh
direction-to-consumer
3/25/26
Apple says it’s bringing ads to its Maps app this summer

That could be another boon for its fast-growing, high-margin Services division.

Daily Life In Melbourne
Target Opens "Target SoHo" - A Design-Forward Shoppable Concept Store In SoHo, New York

As Target alters its dress code, it also wants staff to buy more of its clothes

The retailer’s apparel and accessories sales hit their lowest point since the pandemic last year.

Tom Jones3/25/26

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.
©2026 Sherwood Media, LLC